Article info

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Authors

  • Niklas Klümper Institute for Experimental Oncology, University Hospital Bonn, Bonn, GermanyCenter for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyDepartment of Urology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Jonas Saal Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Fiamma Berner Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Christa Lichtensteiger Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Nina Wyss Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Annkristin Heine Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Franz Georg Bauernfeind Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyMedical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Jörg Ellinger Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyDepartment of Urology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Peter Brossart Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyDepartment of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Stefan Diem Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Sabine Schmid Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Markus Joerger Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Martin Frueh Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, SwitzerlandDepartment of Medical Oncology, University Hospital Bern, Bern, Switzerland PubMed articlesGoogle scholar articles
  • Manuel Ritter Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, GermanyDepartment of Urology, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Michael Hölzel Institute for Experimental Oncology, University Hospital Bonn, Bonn, GermanyCenter for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  • Lukas Flatz Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, SwitzerlandDepartment of Dermatology, Eberhard Karls University Tuebingen, Tuebingen, Germany PubMed articlesGoogle scholar articles
  • Tobias Bald Institute for Experimental Oncology, University Hospital Bonn, Bonn, GermanyCenter for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Tobias Bald; Tobias.Bald{at}ukbonn.de
View Full Text

Citation

Klümper N, Saal J, Berner F, et al
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Publication history

  • Accepted February 14, 2022
  • First published March 15, 2022.
Online issue publication 
March 15, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.